Cambridge Innovation Capital

Cambridge Innovation Capital manages over £600 million and has invested in more than 40 deep-tech and life sciences companies affiliated with the Cambridge ecosystem. It provides early-stage to growth capital and strategic support for startups developing disruptive technologies across therapeutics, medtech/diagnostics, digital health, genomics/proteomics, AI and more. Notable investments include Nuclera (protein expression technology), Microbiotica (microbiome-based therapeutics), CMR Surgical (robotic surgery), Congenica (genomic data interpretation). CIC also owns Start Codon accelerator for life sciences ventures and co-founded DeepTech Labs accelerator for technology businesses. The firm leverages a unique relationship with the University of Cambridge for deal flow and ecosystem access. No direct clinical results—portfolio company results vary.